Abstracts tagged "Biologicals"

Abstract Number: LB11 • ACR Convergence 2025
Efficacy and Safety of Telitacicept in Patients with Sjögren’s Disease: Results from a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Clinical Study
Dong Xu¹, Shangzhu Zhang¹, Lin Qiao¹, Li Zhang¹, Wenxiang Wang², Lin Li², Binghua Xiao², Jing Zhang², Qing Zuraw³, Jianmin Fang² and Xiaofeng Zeng¹, ¹Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases; Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China (People's Republic), ²RemeGen Co., Ltd., Rheumatology, Yantai, China (People's Republic), ³Vor Biopharma Inc., Boston
Background/Purpose: Sjögren's disease (SjD) is a chronic autoimmune disease whose pathogenesis is associated with aberrant activation of B-lymphocytes. Telitacicept, a novel fusion protein, dually targets and…
Abstract Number: LB16 • ACR Convergence 2025
Mepolizumab Reduces End-Organ Manifestations Compared with Standard of Care in Patients with EGPA and HES: A US Real-world Analysis
David Silverman¹, Timothy Barnes², Nnaemeka Odo², Jared Silver³, Lisa Le², Amy Edgecomb⁴ and Hitesh Patel⁵, ¹Rheumatology Department, Kaiser Permanente Colorado Medical Group, Denver, Colorado, ²Value and Evidence Solutions, Optum Life Sciences, Eden Prairie, Minnesota, ³Clinical Development, Amgen, Thousand Oaks, California, ⁴Anti-infectives and Respiratory, GSK, Philadelphia, Pennsylvania, ⁵US Medical Affairs, GSK, Durham, North Carolina
Background/Purpose: Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are rare systemic diseases characterized by persistent eosinophilia and tissue infiltration, resulting in end-organ dysfunction…
Abstract Number: LB06 • ACR Convergence 2025
AgAIN Study: First Head-to-Head Trial of Secukinumab vs. Ustekinumab in TNFα Inhibitor-Experienced Psoriatic Arthritis Patients Reveals Better Efficacy Across Multiple Domains
Frank Behrens¹, Patrizia Sternad², Klaus Krueger³, Christine App⁴, Stephanie Lefevre⁴ and Christiane Schiedel⁴, ¹Department of Rheumatology, Frankfurt University Hospital, Frankfurt, Germany, ²Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ³Rheumatologisches Praxiszentrum, München, Germany, ⁴Novartis Pharma GmbH, Nürnberg, Germany
Background/Purpose: Psoriatic arthritis (PsA) patients with prior failure or intolerance to TNFα inhibitors (TNFi) represent a clinically challenging population with limited therapeutic options. The AgAIN…
Abstract Number: LB09 • ACR Convergence 2025
Rotation or Change of Biologic After TNF blocker treatment failure for axial Spondyloarthritis
Elisa Dalix¹, Philippe Goupille², Daniel Wendling³, Christian Roux⁴, Jean-Hughes Samon⁵, Olivier Brocq⁶, Anne Tournadre⁷, Arnaud Constantin⁸, Maxime Breban⁹, Gregoire Cormier¹⁰, Tristan Pascart¹¹, Thierry Lequerre¹², Pascal Claudepierre¹³, Eric Lespessailles¹⁴, Benoit Legoff¹⁵, Jeremie Sellam¹⁶, Athan Baillet¹⁷, Thierry Schaeverbeke¹⁸, Stephan Pavy¹⁹, Valerie Devauchelle-Pensec²⁰, Elisabeth Gervais²¹, Laure Gossec²², Corinne Miceli²³, Yves-Marie Pers²⁴, Cedric Lukas²⁵, Renaud Felten²⁶, Beatrice Bouvard²⁷, Amelie Denis²⁸, Emmanuelle Dernis²⁸, Emilie Presles²⁹, Florence Rancon²⁹ and Hubert Marotte³⁰, ¹Université Jean Monnet, CHU Saint-Etienne, Mines Saint-Etienne, INSERM, Saint-Etienne, France, ²Department of Rheumatology and INSERM-CIC¹⁴¹⁵, University Hospital of Tours, EA ⁷⁵⁰¹ GICC, University of Tours, Tours, France, ³Rhumatologie, CHU de Besançon, Besancon, France, ⁴Service de rhumatologie, CHU de Nice, IbV, Université Cote d'Azur, Nice, France, ⁵Service de Rhumatologie, Hôpital Maison Blanche, Centre Hospitalier Universitaire de Reims, Reims, France; Université de Reims Champagne-Ardenne, Faculté de Médicine, EA ³⁷⁹⁷, Reims, France, ⁶Rheumatology Department, CHPG Monaco, Monaco, Monaco, ⁷Rheumatology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France, ⁸Rheumatology Center, Toulouse University Hospital, Toulouse, France, ⁹INSERM UMR¹¹⁷³, INFLAMEX, Laboratoire d'Excellence, Rheumatology Division, Ambroise Paré Hospital (AP-HP), Paris, France, ¹⁰Rheumatology, Centre Hospitalier Departemental Vendee, La Roche-sur-Yon, France, ¹¹Department of Rheumatology, Université Catholique de Lille Hôpital Saint Philibert, Lomme, France, ¹²Department of Rheumatology & CIC-CRB ¹⁴⁰⁴, Inserm, PANTHER UMR ¹²³⁴, University of Rouen Normandie, Normandie University, CHU Rouen, Rouen, France, ¹³AP-HP, Henri-Mondor Hospital, Department of Rheumatology, EpiDermE, Université Paris Est Créteil, Créteil, France, ¹⁴Translational Medicine Research Platform, PRIMMO, University Hospital Centre of Orleans, Orleans, France, ¹⁵Nantes Université, ONIRIS, Univ Angers, CHU Nantes, INSERM, Regenerative Medicine and Skeleton, RMeS, UMR ¹²²⁹, Nantes, France, ¹⁶Rheumatology Department, Sorbonne Université, Saint-Antoine Hospital Assistance Publique Hôpitaux de Paris (AP-HP), Centre de Recherche Saint-Antoine (CRSA) Inserm UMRS-⁹³⁸,, Paris, France, ¹⁷Université Grenoble Alpes, ⁴UMR⁵⁵²⁵, Grenoble, France, ¹⁸Department of Rheumatology, Hôpital Pellegrin, Bordeaux, France, ¹⁹Department of Rheumatology, Hôpital Bicêtre, Assistance Publique - Hôpitaux de Paris, Le Kremlin-Bicetre, ²⁰Department of Rheumatology, Université de Bretagne Occidentale, CHU Brest, INSERM (U¹²²⁷), LabEx IGO, Brest, France, ²¹LITEC, Université de Poitiers, CHU Poitiers, Poitiers, France, ²²Sorbonne Université, AP-HP & EULAR, Paris, France, ²³Immunoregulation Unit, Institut Pasteur, Cochin AP-HP, Paris, France, ²⁴IRMB, University of Montpellier, Inserm U¹¹⁸³, CHU Montpellier, Montpellier, France, ²⁵Rheumatology department, CHU and University of Montpellier, Montpellier, France; UMR UA¹¹ Inserm (IDESP), University of Montpellier, Montpellier, France, ²⁶Service de Rhumatologie, CHU de Strasbourg - Hôpital de Hautepierre, Strasbourg, France, ²⁷Rhumatologie, Centre Hospitalier Universitaire, Angers, France, ²⁸CH Le Mans, Le Mans, France, ²⁹CHU Saint-Etienne, CIC ¹⁴⁰⁸, Saint-Etienne, France, ³⁰Université Jean Monnet, CHU de Saint-Etienne, CIC ¹⁴⁰⁸, Mines Saint-Etienne, INSERM, SSINBIOSE ¹⁰⁵⁹, Saint-Etienne, France
Background/Purpose: Axial spondyloarthritis (axSpA) is initially treated with non-steroidal anti-inflammatory drugs. In case of inadequate response, ACR/EULAR recommend biological disease-modifying antirheumatic drugs (bDMARDs). Up to…
Abstract Number: 2477 • ACR Convergence 2025
Current treatment Strategies in Systemic Sclerosis- Interstitial Lung Disease Patients: Real-World Insights from the EUSTAR Cohort (CP138)
Corrado Campochiaro¹, Marie-Elise Truchetet², Madelon Vonk³, Giacomo De Luca⁴, Giovanna Cuomo⁵, Lidia P Ananieva⁶, Eric Hachulla⁷, Vanessa Smith⁸, Ana Maria Gheorghiu⁹, Radim Bečvář¹⁰, Patricia E. Carreira¹¹, Nicolas Hunzelmann¹², Daniel Furst¹³, Vera Ortiz-Santamaria¹⁴, Francesco Del Galdo¹⁵, Marco Matucci-Cerinic¹⁶ and Anna-Maria Hoffmann-Vold¹⁷, ¹IRCCS San Raffaele Hospital. Vita-Salute San Raffaele University, Milan, Milan, Italy, ²Bordeaux University Hospital, Bordeaux, France, ³Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁴Vita-Salute San Raffaele University & IRCCS San Raffaele Hospital, Milan, Italy, ⁵Department of Precision Medicine, University Hospital Luigi Vanvitelli, Naples, Italy, Naples, Italy, ⁶A Nasonova Institute of Rheumatology, Moscow, Russian Federation, Moscow, Russia, ⁷University of Lille, LILLE, France, ⁸Ghent University Hospital, Gent, Belgium, ⁹Spitalul Clinic Dr. Ion Cantacuzino, Bucharest, Romania, ¹⁰Department of Internal Medicine, Charles University,, Prague, Czech Republic, ¹¹Hospital Universitario ¹² de Octubre, Madrid, Spain, ¹²Department of Dermatology and Venereology, University Hospital Cologne, Cologne, Germany, ¹³Southern California Scleroderma and Rheumatology Center, Los Angeles, CA, ¹⁴HOSP. GENERAL DE GRANOLLERS, Barcelona, Spain, ¹⁵University of Leeds, Leeds, United Kingdom, ¹⁶University San Raffaele Milano, Milano, Milan, Italy, ¹⁷Oslo University Hospital, Oslo, Norway
Background/Purpose: The therapeutic landscape for systemic sclerosis- interstitial lung disease (SSc-ILD) has rapidly evolved over the past decade, with increasing adoption of immunosuppressive (IST) and…
Abstract Number: 2354 • ACR Convergence 2025
ChatGPT or SPSS? A comparison between AI-based and Traditional Statistical Analysis of Longitudinal Inflammatory Marker Data in Spondyloarthritis
José Miguel Sequí-Sabater¹, Pablo Beltrán Martin-Lorente², Sonia Pastor Navarro³, Maria del Carmen Lopez Gonzalez⁴, Maria Sanchez-Wonenburger⁵, DESAMPARADOS CASADO POVEDA³ and Anna Martínez Cristóbal⁶, ¹La Ribera University Hospital, Rheumatology Department, Gandía, Spain, ²Universidad Católica de Valencia "San Vicente Mártir", Valencia, Comunidad Valenciana, Spain, ³La Ribera University Hospital, Rheumatology Department, Valencia, Comunidad Valenciana, Spain, ⁴La Ribera University Hospital, Rheumatology Department, Cullera, Comunidad Valenciana, Spain, ⁵Hospital Universitario de La Ribera, València, Comunidad Valenciana, Spain, ⁶La Ribera University Hospital, Rheumatology Department, Alzira, Comunidad Valenciana, Spain

Background/Purpose: While traditional analysis relies on statistical software such as SPSS, emerging tools like ChatGPT introduce the possibility of performing statistical tests, interpreting results, and…
Abstract Number: 2143 • ACR Convergence 2025
Ruxolitinib for Refractory sJIA/AOSD: A Single Center Case Series
Jacqueline Madison¹, Andrew Grim² and Janna Shim³, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Medicine, Ann Arbor, MI, ³Midwestern University Chicago College of Osteopathic Medicine, Downers Grove
Background/Purpose: Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult-onset Still’s disease (AOSD) are rare, chronic, autoinflammatory diseases distinct from other forms of chronic inflammatory arthritis. Potential…
Abstract Number: 1629 • ACR Convergence 2025
Real-World Effectiveness of Interleukin-6 Receptor Inhibitors Compared to Methotrexate in Steroid-Refractory Frail Patients with Polymyalgia Rheumatica
Sebastian E Sattui¹, Christian Dejaco², Kerri Ford³, Stefano Fiore⁴, Sebastian H Unizony⁵, Fenglong Xie⁶ and Jeffrey Curtis⁷, ¹Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ²Medical University of Graz, Department of Rheumatology, Graz, Austria; Department of Rheumatology, Hospital of Brunico (SABES-ASDAA), Brunico, Italy, ³Sanofi, Cambridge, MA, ⁴Sanofi, Morristown, NJ, ⁵Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶The University of Alabama at Birmingham, Birmingham, AL, ⁷Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: A previous post hoc analysis of frail (defined by claims-based frailty index [CFI] ≥0.2) patients with PMR on second line (2L) and 3L treatment…
Abstract Number: 1463 • ACR Convergence 2025
Effective Prevention of Psoriatic Arthritis with Secukinumab: A 5-Year Observation from the SERENA Study
Uta Kiltz¹, Petros Sfikakis², Andreas Bounas³, Nicola Gullick⁴, Eric LESPESSAILLES⁵, Jan Brandt-Juergens⁶, Rasho Rashkov⁷, Cynthia Vizcaya⁸, Andreas Clemens⁸, Weibin Bao⁹ and Karl Gaffney¹⁰, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²NKUA - SCHOOL OF MEDICINE, Athens, Greece, ³‘OLYMPION’, General Clinic of Patra, Patra, Greece, ⁴Rheumatology Department, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK, Coventry, United Kingdom, ⁵University Hospital of Orléans, Orleans, France, ⁶Rheumatologische Schwerpunktpraxis, Berlin, Germany, ⁷Clinic of Rheumatology, University Hospital St. Ivan Rilski, Sofia, Bulgaria, ⁸Novartis Pharma AG, Basel, Switzerland, ⁹Novartis Pharmaceuticals Corporation, Hanover, NJ, ¹⁰Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, United Kingdom
Background/Purpose: Secukinumab, an IL-17A inhibitor, has well-established effectiveness in the treatment of psoriasis (PsO) and psoriatic arthritis (PsA) in both long-term clinical trials and the…
Abstract Number: 1365 • ACR Convergence 2025
Economic impact of early treatment and strict disease control in rheumatoid arthritis: a cost-minimization approach concerning biological therapy
Raianni Rúbia Pacheco Silva¹, Daniel da Silva Pereira Curado², Paula Cristina Montina², Everton Nunes da Silva³, Ana Paula Monteiro Gomides², Rina Dalva Neubarth Giorgi⁴, Leticia Rocha Pereira⁵, Sebastião Cezar Radominski⁶, Ivanio Alves Pereira⁷, Maria Fernanda Brandão de Resende Guimarães⁸, Manoel Barros Bertolo⁹, Paulo Louzada Junior¹⁰, Maria de Fátima Lobato da Cunha Sauma¹¹, Karina Rossi Bonfiglioli⁵, Claiton Viegas Brenol¹², Geraldo da Rocha Castelar Pinheiro¹³, Cleandro Pires de Albuquerque² and Licia Maria Henrique da Mota¹⁴, ¹Universidade de Brasília, Brasília, Distrito Federal, Brazil, ²Universidade de Brasília, Brasília, Brazil, ³Universidade de Brasília, brasilia, Brazil, ⁴IAMSPE, São Paulo, Brazil, ⁵Hospital do Servidor Público Estadual de São Paulo, São Paulo, Brazil, ⁶UFPR, Curitiba, Brazil, ⁷UFSC, Florianopolis, Brazil, ⁸UFMG, Belo Horizonte, Brazil, ⁹Unicamp, Campinas, Brazil, ¹⁰USP-RP, Ribeirão Preto, Brazil, ¹¹UFPA, Belem, Brazil, ¹²UFRGS, Porto Alegre, Brazil, ¹³UERJ, Rio de Janeiro, Brazil, ¹⁴UNB, Brasilia, Distrito Federal, Brazil
Background/Purpose: Rheumatoid arthritis (RA) is a chronic, progressive, potentially disabling autoimmune disease, with substantial economic burden, particularly related to its high-cost pharmacological treatment. Early treatment,…
Abstract Number: 1165 • ACR Convergence 2025
Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Tumor Necrosis Factor Inhibitors
Philip J. Mease¹, Jessica A. Walsh², Timothy P. Fitzgerald³, Soumya Chakravarty⁴, Elizabeth Adamson⁵, Bruno Emond⁶, Carmine Rossi⁷, Samuel Schwartzbein⁷, Kana Yokoji⁷, Yuxi Wang⁷, Patrick Lefebvre⁷, Dominic Pilon⁷, Shikha Singla⁸ and Joseph F Merola⁹, ¹Department of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, ²Division of Rheumatology, Salt Lake City Veterans Affairs Health and University of Utah Health, Salt Lake City, UT, ³Johnson & Johnson, Horsham, PA, USA, PA, ⁴Johnson & Johnson, Horsham, PA, USA; Drexel University College of Medicine, Philadelphia, PA, USA, Villanova, PA, ⁵Johnson & Johnson, Horsham, PA, USA, Horsham, PA, ⁶Analysis Group, Inc., Montreal, QC, Canada, QC, ⁷Analysis Group, Inc., Montreal, QC, Canada, QC, Canada, ⁸Medical College of Wisconsin, Milwaukee, WI, ⁹Department of Dermatology and Department of Medicine, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: A prior analysis found that patients (pts) with psoriatic arthritis (PsA) treated with guselkumab (GUS), an IL-23p19 subunit inhibitor, were approximately 2× more likely…
Abstract Number: 0941 • ACR Convergence 2025
In Vivo PanCAR Therapy Utilizing Circular RNA for Treatment of Autoimmune Diseases
Juliet Crabtree, Thomas Lee, David Soto, Prapti Vyas, Akinola Emmanuel, Matthew Theisen, Karolina Kosakowska, Maja Sedic, Rajat Das, Muthusamy Jayaraman, Megan Hoban, Joe Bolen and Isin Dalkilic-Liddle, Orna Therapeutics, watertown, MA
Background/Purpose: Recently, traditional ex vivo-generated chimeric antigen receptor T (CAR-T) cell therapies have shown success in the clinic for autoimmunity indications. However, manufacturing, safety, and…
Abstract Number: 0886 • ACR Convergence 2025
A First-in-Class Biologic Selectively Targeting HLA-B27-Reactive T Cells in Ankylosing Spondylitis
Patrick Holec, Megan Reitars, Nishant Singh and Isabelle Larsen, Fletcher Biosciences, Cambridge, MA
Background/Purpose: Ankylosing spondylitis (AS), a chronic autoimmune disease strongly associated with HLA-B27:05, is currently managed with therapies that broadly suppress inflammation instead of targeting disease-driving…
Abstract Number: 0499 • ACR Convergence 2025
Olokizumab Improves Patient-Reported Outcomes in Rheumatoid Arthritis MTX-IR and TNF-IR Patients up to 106 Weeks (Results from Clinical Phase III Program)
Roy Fleischmann¹, Eugen feist² and Josef Smolen³, ¹Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX, ²Helios Department of Rheumatology, Vogelsang-Gommern, Germany, ³Division of Rheumatology, Department of Medicine ³, Medical University of Vienna, Vienna, Austria, Vienna, Austria
Background/Purpose: Olokizumab (OKZ), an interleukin-6 inhibitor approved in several countries for managing rheumatoid arthritis (RA), was evaluated in previous phase III RCTs, demonstrating changes in…
Abstract Number: 0241 • ACR Convergence 2025
Efficacy and Safety of JAK Inhibitors in Behçet’s Syndrome: A Systematic Literature Review
Bercemhan Sulu¹, Sinem Nihal Esatoglu¹, Ibrahim Hatemi², Aykut Ferhat Celik³ and Gulen Hatemi¹, ¹Istanbul University-Cerrahpasa, Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Rheumatology, Istanbul, Turkey, ²Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty, Department of Internal Medicine, Division of Gastroenterology, Istanbul, Turkey, ³Istanbul University-Cerrahpasa / Cerrahpasa Medical Faculty / Department of Internal Medicine / Division of Gastroenterology, Istanbul, Turkey
Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are a key treatment modality for major organ involvement, one of the main contributors to morbidity and mortality, as…

1
2
3
…
67
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].